Announcement on Preliminary Earnings Estimate for 2024
Filed with SSE · · 4 pages · Chinese
Frontier Biotechnologies Inc. on 6ix
Earlier from Frontier Biotechnologies
- Announcement on Voluntary Disclosure of the Notice of Acceptance for Registration and Marketing License of FB3002 Loxoprofen Sodium Patches Obtained for Drug Manufactured in China
- Voluntary Disclosure Announcement on Approval of Phase II Clinical Trial for New Indication of Immune Reconstitution Insufficient of Aikening
- Announcement on Resolutions of the 4th Extraordinary General Meeting in 2024
- Announcement on Resolution of the 18th Meeting of the 3rd Board of Supervisors
- Announcement on the Renewal of Company Product Albuvirtide for Injection for Inclusion in the Catalogue of Drugs for Basic National Medical Insurance
Later from Frontier Biotechnologies
- Announcement on Attending the Annual Collective Performance Briefing for Innovative Drug Companies on SSE STAR Market 2024 and Convening the Q1 2025 Performance Briefing
- Announcement on Signing the Supplementary Agreement and Passive Extension of Related Party Loans
- Announcement on Resolution of the 2024 Annual General Meeting
- Announcement on Change of Sponsor Representative
- Announcement on Reply to the Regulatory Inquiry Letter on Information Disclosure of 2024 Annual Report
Follow Frontier Biotechnologies into a list and get an email when it puts out news.
Follow Frontier Biotechnologies